Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US House Panel Passes Bill To Bring More Transparency To Local Coverage Determination Process

Executive Summary

The House Ways and Means Committee advanced legislation backed by the device industry to improve the transparency and accountability of the process Medicare Administrative Contractors use to make local coverage determinations for new medical technology.

You may also be interested in...



Medtech Bill Sponsor Sen. Isakson Retiring At Year’s End

Sen. Johnny Isakson, R-GA, who has sponsored and backed several key pieces of device-industry legislation over the last several years, said on 28 August that he will retire from the US Senate on 31 December 2019, due to health challenges.

CMS Head Verma Unveils Favorable Coding Changes For Medtech, Pharma At MDMA Meeting

The US Centers for Medicare and Medicaid Services will allow device manufacturers to submit requests for HCPCS codes for emerging technology on a semi-annual basis, and drug-makers will be allowed to submit quarterly, CMS chief Seema Verma told an MDMA audience at the industry advocacy group's annual meeting on 2 May.

3 Big Medtech Takeaways From US Midterms

The balance of power will be shifting in Washington, DC, following the Nov. 6 US midterm elections, but that probably will not mean major changes for medtech policies. Here are some key takeaways from the election for device and diagnostics companies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel